T11	Subject 51 159	children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma
T13	Treatment 0 49;187 450	After completion of induction-consolidation phase four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B)
T14	Age 51 59	children
T15	Treat-Disorder 137 159	lymphoblastic lymphoma
T18	Drug 203 209	HD MTX
T19	Dosage 211 219	5 g/m(2)
T20	Freq 220 247	over 24 hours every 2 weeks
T21	Drug 289 292	MTX
T22	Drug 348 359	HD IV Ara-C
T23	Dosage 361 369	1 g/m(2)
T24	Route 373 388	bolus injection
T26	Drug 429 432	MTX
T12	Potential_therapeutic_event 179 186	receive
T25	Combination 332 336	with
E1	Potential_therapeutic_event:T12 
E2	Combination:T25 arg:T21 arg2:T22
